![]() |
市场调查报告书
商品编码
1872194
胞浆素原:全球市场份额和排名、总收入和需求预测(2025-2031年)Plasminogen - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
2024 年全球胞浆素原市场规模估计为 1,180 万美元,预计到 2031 年将达到 1.18 亿美元,在 2025 年至 2031 年的预测期内,复合年增长率将达到 39.5%。
胞浆素原原是纤溶酶的胞浆素酶,是一种单链糖蛋白,分子量约90,000–94,000道尔顿(2)。它以多种等电点形式存在,可透过等电聚焦(IEF)进行分离。其完整的胺基酸序列包含790个胺基酸。天然胞浆素原(麸胺酸型胞浆素原)的N端带有麸胺酸残基。在血浆中发生部分蛋白水解后,会产生N端带有离胺酸残基的分子(离胺酸型胞浆素原)。目前,它已获得美国食品药物管理局(FDA)和欧洲药品管理局(EMA)的孤儿药资格认定。 2021年,美国食品药物管理局 )核准了Leiprazim(胞浆素原,人源tvmh)用于治疗第1型胞浆素原原缺乏症(也称为胞浆素原)。该疾病会损害正常组织和器官功能,并可能导致失明。本报告主要涵盖胞浆素原市场的研究成果、预测的竞争格局、市场潜力及未来趋势。
胞浆素原市场的主要驱动力在于其在溶栓和溶栓治疗中的关键作用,它用于溶解血栓并治疗相关疾病,例如深层静脉栓塞症、肺动脉栓塞和心肌梗塞。随着全球心血管疾病和凝血障碍的盛行率持续上升,对胞浆素原原治疗方法的需求也稳定成长。此外,胞浆素原在胞浆素原缺乏症等罕见疾病中的应用,进一步巩固了该市场在特殊治疗领域的重要性。纤溶酶原缺乏症可导致严重的组织损伤和视力丧失。
除了治疗应用外,创伤治疗、组织修復和眼睛健康的研究也推动了胞浆素原市场的发展。生物製药和创新药物递送系统的进步正在拓展胞浆素原原类产品的应用范围。然而,高昂的治疗成本、血浆衍生产品的供应有限以及严格的监管核准流程等挑战依然存在。儘管存在这些障碍,但正在进行的临床试验以及人们对纤溶药物日益增长的认识有望在未来几年创造新的发展机会。
本报告旨在按地区/国家、类型和应用对全球胞浆素原原市场进行全面分析,重点关注总收入、市场份额和主要企业的排名。
本报告以2024年为基准年,按销售收入对胞浆素原原市场规模、估算和预测进行了阐述,并包含了2020年至2031年的历史数据和预测数据。报告采用定量和定性分析相结合的方法,旨在帮助读者制定业务/成长策略,评估市场竞争格局,分析自身在当前市场中的地位,并就胞浆素原原市场做出明智的商业决策。
市场区隔
公司
按类型分類的细分市场
应用领域
按地区
The global market for Plasminogen was estimated to be worth US$ 11.8 million in 2024 and is forecast to a readjusted size of US$ 118 million by 2031 with a CAGR of 39.5% during the forecast period 2025-2031.
Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF). The complete amino acid sequence contains 790 amino acids. Native plasminogen (glu-plasminogen) has a N-terminal glutamic acid group. Partial plasma proteolysis gives rise to a molecule with N-terminal lysine (lysplasminogen). Currently, the product has obtained the designation of orphan drug by the US Food and Drug Administration (FDA) and by the European Medicines Agency (EMA). In 2021, U.S. Food and Drug Administration approved Ryplazim (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1, also referred to as hypoplasminogenemia, a disorder that can impair normal tissue and organ function and may lead to blindness. The report mainly targeting the research status, predicted competitive landscape, market potential and future trends of plasminogen market.
The plasminogen market is primarily driven by its critical role in fibrinolysis and thrombolytic therapy, where it is used to dissolve blood clots and treat related conditions such as deep vein thrombosis, pulmonary embolism, and myocardial infarction. As the prevalence of cardiovascular diseases and clotting disorders continues to rise globally, demand for plasminogen-based therapies is growing steadily. Additionally, the use of plasminogen in rare diseases such as plasminogen deficiency, which can cause severe tissue damage and vision loss, further strengthens the market's importance in specialized treatment areas.
Beyond therapeutic applications, the plasminogen market is also supported by research activities focused on wound healing, tissue repair, and ocular health. Biopharmaceutical advancements and innovative drug delivery systems are expanding the scope of plasminogen-based products. However, the market faces challenges such as the high cost of therapies, limited availability of plasma-derived products, and stringent regulatory approval processes. Despite these hurdles, ongoing clinical trials and growing awareness of fibrinolytic agents are expected to create new opportunities for expansion in the coming years.
This report aims to provide a comprehensive presentation of the global market for Plasminogen, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Plasminogen by region & country, by Type, and by Application.
The Plasminogen market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Plasminogen.
Market Segmentation
By Company
Segment by Type
Segment by Application
By Region
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Plasminogen company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Plasminogen in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Plasminogen in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.